Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

52.95 UNCHANGED

Last Price Updated: 4:15 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 31, 2024

Via Benzinga

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

October 07, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments ↗

September 18, 2024

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Via The Motley Fool

Top 2 Health Care Stocks That May Collapse This Quarter ↗

September 09, 2024

Via Benzinga

Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday ↗

September 18, 2024

Via Benzinga

Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. ↗

September 15, 2024

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Via The Motley Fool

Should You Invest in This Under-the-Radar Weight Loss Stock? ↗

September 15, 2024

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

Via The Motley Fool

1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More ↗

September 14, 2024

This biotech's data suggests that it could have an advantage in its target market.

Via The Motley Fool

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 12, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Announces Pricing of Upsized $150.15 Million Public Offering

September 10, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday ↗

September 10, 2024

Via Benzinga

Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 10, 2024

Via Benzinga

Terns Announces Proposed Public Offering

September 09, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month ↗

September 09, 2024

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the...

Via Benzinga

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

September 09, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 ↗

August 05, 2024

TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

August 05, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Have Investors Grinning Soon ↗

August 02, 2024

Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.

Via InvestorPlace

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

August 01, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

July 29, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗

July 20, 2024

At least one of the pair has a credible shot at finding a home in the market.

Via The Motley Fool

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 11, 2024

Via Benzinga

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

June 21, 2024

TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean...

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

June 03, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 30, 2024

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.